BE2017C028I2 - - Google Patents

Info

Publication number
BE2017C028I2
BE2017C028I2 BE2017C028C BE2017C028C BE2017C028I2 BE 2017C028 I2 BE2017C028 I2 BE 2017C028I2 BE 2017C028 C BE2017C028 C BE 2017C028C BE 2017C028 C BE2017C028 C BE 2017C028C BE 2017C028 I2 BE2017C028 I2 BE 2017C028I2
Authority
BE
Belgium
Application number
BE2017C028C
Other languages
French (fr)
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2017C028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of BE2017C028I2 publication Critical patent/BE2017C028I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2017C028C 2005-01-26 2017-08-03 BE2017C028I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (en) 2005-01-26 2006-01-25 ANTICANCER DRUG CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR

Publications (1)

Publication Number Publication Date
BE2017C028I2 true BE2017C028I2 (en) 2025-09-10

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2017C028C BE2017C028I2 (en) 2005-01-26 2017-08-03

Country Status (20)

Country Link
EP (1) EP1849470B2 (en)
JP (1) JP5576591B2 (en)
KR (1) KR101468216B1 (en)
AU (1) AU2006209547C1 (en)
BE (1) BE2017C028I2 (en)
CA (1) CA2594713A1 (en)
CY (2) CY2017029I2 (en)
DK (1) DK1849470T4 (en)
ES (1) ES2630002T5 (en)
FI (1) FI1849470T4 (en)
FR (1) FR17C1028I2 (en)
HU (2) HUE033306T2 (en)
LT (2) LT1849470T (en)
LU (1) LUC00036I2 (en)
NL (1) NL300889I2 (en)
PL (1) PL1849470T5 (en)
PT (1) PT1849470T (en)
SI (1) SI1849470T2 (en)
TW (1) TWI362265B (en)
WO (1) WO2006080327A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
DE102004032049A1 (en) 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DE102005005449A1 (en) 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
PL2148676T3 (en) * 2007-04-25 2016-12-30 Use of sapacitabine to treat proliferative disease
TWI454288B (en) 2008-01-25 2014-10-01 Gruenenthal Chemie Pharmaceutical dosage form
ES2599031T3 (en) 2008-05-09 2017-01-31 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spray freezing step
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
BR112012001466A2 (en) 2009-07-22 2020-08-11 Grünenthal GmbH counterfeit-resistant dosage form for oxidation-sensitive opioids, their manufacturing process, and packaging
ES2534908T3 (en) 2009-07-22 2015-04-30 Grünenthal GmbH Hot melt extruded controlled release dosage form
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (en) 2011-07-29 2017-02-21 Gruenenthal Gmbh tamper-resistant tablet providing immediate drug release
JP6063462B2 (en) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Tamper-resistant tablets that provide immediate drug release
PL2746404T3 (en) 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI503122B (en) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (en) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
BR112014019988A8 (en) 2012-02-28 2017-07-11 Gruenenthal Gmbh BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER
LT2838512T (en) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104349779A (en) * 2012-05-16 2015-02-11 诺华股份有限公司 Dosage regimen for a pi-3 kinase inhibitor
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
UA114840C2 (en) * 2013-03-27 2017-08-10 Тайхо Фармасьютікал Ко., Лтд. ANTI-TUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRAUL
JP6312660B2 (en) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Method for predicting therapeutic effect on colorectal cancer patients with enhanced expression of TK1 protein
MX2015016254A (en) 2013-05-29 2016-04-20 Gruenenthal Gmbh Tamper resistant dosage form with bimodal release profile.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer
HK1224189A1 (en) 2013-11-26 2017-08-18 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3693019A1 (en) 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
KR102412690B1 (en) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 Treatment method for cancer patients with severe renal dysfunction
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD FOR DETECTING ANALOGS DERIVED FROM TRIFLURIDINE AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (en) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 Detection method for analog derived from trifluridine
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (en) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 Uracil derivatives and antitumor effect enhancers and antitumor agents containing the same
EP0884051B1 (en) * 1996-09-24 2004-12-15 Taiho Pharmaceutical Company Limited Cancerous metastasis inhibitors containing uracil derivatives
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Also Published As

Publication number Publication date
RU2007132181A (en) 2009-03-10
JPWO2006080327A1 (en) 2008-06-19
LUC00036I2 (en) 2017-12-01
FR17C1028I2 (en) 2018-11-02
LUC00036I1 (en) 2017-10-02
PL1849470T3 (en) 2017-11-30
ES2630002T5 (en) 2024-09-19
DK1849470T4 (en) 2024-04-02
CY2017029I1 (en) 2018-02-14
JP5576591B2 (en) 2014-08-20
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (en) 2019-10-25
ES2630002T3 (en) 2017-08-17
AU2006209547A1 (en) 2006-08-03
TW200637562A (en) 2006-11-01
CY2017029I2 (en) 2018-02-14
SI1849470T2 (en) 2024-05-31
TWI362265B (en) 2012-04-21
SI1849470T1 (en) 2017-10-30
PL1849470T5 (en) 2024-06-10
NL300889I2 (en) 2018-01-16
AU2006209547B2 (en) 2011-05-26
FI1849470T4 (en) 2024-03-22
AU2006209547C1 (en) 2022-04-07
EP1849470A1 (en) 2007-10-31
EP1849470B2 (en) 2024-03-20
HUS1700032I1 (en) 2017-09-28
NL300889I1 (en) 2017-08-14
CA2594713A1 (en) 2006-08-03
PT1849470T (en) 2017-09-22
LTPA2017024I1 (en) 2017-08-10
CY1119393T1 (en) 2018-02-14
EP1849470B1 (en) 2017-06-21
WO2006080327A1 (en) 2006-08-03
KR101468216B1 (en) 2014-12-03
LT1849470T (en) 2017-07-25
FR17C1028I1 (en) 2017-09-29
HUE033306T2 (en) 2017-11-28
KR20070104559A (en) 2007-10-26
DK1849470T3 (en) 2017-08-14
RU2394581C2 (en) 2010-07-20

Similar Documents

Publication Publication Date Title
BE2025C533I2 (en)
BE2023C529I2 (en)
BE2021C552I2 (en)
BE2021C557I2 (en)
BE2021C531I2 (en)
BE2021C519I2 (en)
BE2020C531I2 (en)
BE2020C511I2 (en)
BE2019C521I2 (en)
BE2019C503I2 (en)
BE2018C037I2 (en)
BE2018C035I2 (en)
BE2018C019I2 (en)
LUC00036I1 (en)
BE2019C533I2 (en)
BE2017C007I2 (en)
BE2016C045I2 (en)
BE2016C022I2 (en)
BE2015C074I2 (en)
BE2014C012I2 (en)
BE2014C057I2 (en)
BE2013C014I2 (en)
BE2012C042I2 (en)
BE2012C028I2 (en)
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico